NO178975C - Fremgangsmåte til transformering av en gjærart av slekten Pichia - Google Patents

Fremgangsmåte til transformering av en gjærart av slekten Pichia

Info

Publication number
NO178975C
NO178975C NO854334A NO854334A NO178975C NO 178975 C NO178975 C NO 178975C NO 854334 A NO854334 A NO 854334A NO 854334 A NO854334 A NO 854334A NO 178975 C NO178975 C NO 178975C
Authority
NO
Norway
Prior art keywords
genus pichia
transforming
yeast species
yeast strains
disclosed
Prior art date
Application number
NO854334A
Other languages
English (en)
Norwegian (no)
Other versions
NO178975B (no
NO854334L (no
Inventor
David Womack Stroman
James Michael Cregg
Michael Miller Harpold
George Thomas Sperl
Original Assignee
Res Corp Technologies Inc
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc, Phillips Petroleum Co filed Critical Res Corp Technologies Inc
Publication of NO854334L publication Critical patent/NO854334L/no
Publication of NO178975B publication Critical patent/NO178975B/no
Publication of NO178975C publication Critical patent/NO178975C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Tires In General (AREA)
NO854334A 1984-10-30 1985-10-30 Fremgangsmåte til transformering av en gjærart av slekten Pichia NO178975C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/666,579 US4879231A (en) 1984-10-30 1984-10-30 Transformation of yeasts of the genus pichia

Publications (3)

Publication Number Publication Date
NO854334L NO854334L (no) 1986-05-02
NO178975B NO178975B (no) 1996-04-01
NO178975C true NO178975C (no) 1996-07-10

Family

ID=24674609

Family Applications (1)

Application Number Title Priority Date Filing Date
NO854334A NO178975C (no) 1984-10-30 1985-10-30 Fremgangsmåte til transformering av en gjærart av slekten Pichia

Country Status (18)

Country Link
US (1) US4879231A (fr)
EP (1) EP0183070B1 (fr)
JP (1) JPH0681593B2 (fr)
AT (1) ATE68204T1 (fr)
AU (1) AU572353B2 (fr)
CA (1) CA1297438C (fr)
DE (1) DE3584353D1 (fr)
DK (1) DK496485A (fr)
ES (1) ES8609464A1 (fr)
FI (1) FI94428C (fr)
GR (1) GR852609B (fr)
IE (1) IE58217B1 (fr)
IL (1) IL76763A (fr)
MX (1) MX430A (fr)
NO (1) NO178975C (fr)
PT (1) PT81402B (fr)
SG (1) SG43092G (fr)
ZA (1) ZA858180B (fr)

Families Citing this family (470)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA872534B (en) * 1986-05-08 1987-11-25 Phillips Petroleum Co Yeast production of streptokinase
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
IL89989A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
US5204252A (en) * 1989-02-08 1993-04-20 Henkel Research Corporation Candida tropicalis transformation system
WO1990009434A1 (fr) * 1989-02-13 1990-08-23 The Salk Institute Biotechnology/Industrial Associates, Inc. Production de peroxyde dismutase dans des cellules de levure de pichia pastoris
US5254466A (en) * 1989-11-06 1993-10-19 Henkel Research Corporation Site-specific modification of the candida tropicals genome
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992013951A1 (fr) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production de serumalbumine humaine dans des cellules de levure methylotrophique
WO1992017595A1 (fr) * 1991-04-01 1992-10-15 The Salk Institute Biotechnology/Industrial Associates, Inc. Genes influançant l'activite proteolytique de pichia, et leurs utilisations
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US5665600A (en) * 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
AU664469B2 (en) 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
PL310523A1 (en) * 1993-03-03 1995-12-27 Du Pont Method of producing glycolane oxidase in methylothrophic yeast
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (fr) * 1994-10-18 1996-04-25 George Phillip Vlasuk Proteines anticoagulantes et inhibiteurs de la serine-protease extraits de nematodes
DK0788546T3 (da) * 1994-10-18 2007-04-10 Dendreon Corp Nematode-ekstraherede serinproteaseinhibitorer og antikoagulerende proteiner
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
WO1997017451A2 (fr) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Production de gad65 dans une levure methylotrophe
IL125073A0 (en) 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
US5736383A (en) * 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) * 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
MX9605082A (es) 1996-10-24 1998-04-30 Univ Autonoma De Nuevo Leon Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
KR100856995B1 (ko) 1997-04-07 2008-09-04 제넨테크, 인크. 인간화 항체 및 인간화 항체의 제조 방법
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE69839942D1 (de) 1997-10-29 2008-10-09 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
DE69840051D1 (de) 1997-10-29 2008-11-06 Genentech Inc Durch wnt-1 induzierbare gene
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
EP1865061A3 (fr) 1998-05-15 2007-12-19 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6316245B1 (en) * 1998-09-16 2001-11-13 Biongene Co., Ltd. Mutant cells of Pichia
EP1950300A3 (fr) 1998-11-18 2011-03-23 Genentech, Inc. Variantes d'anticorps avec une affinité de liaison plus élevée en comparaison aux anticorps parents
EP1820859B9 (fr) 1998-12-22 2009-10-28 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6720174B1 (en) 1999-01-28 2004-04-13 Novozymes A/S Phytases
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
AU7878900A (en) * 1999-10-15 2001-04-30 Heska Corporation Method for production and use of mite group 1 proteins
CA2494705A1 (fr) 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
EP2290081A3 (fr) 1999-12-23 2012-08-01 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
WO2001077351A1 (fr) * 2000-04-07 2001-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vecteurs et procedes d'expression de proteine double dans pichia pastoris et escherichia coli
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
EP2075253A1 (fr) 2000-06-23 2009-07-01 Genentech, Inc. Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
KR100787073B1 (ko) * 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
CA2411968C (fr) 2000-06-30 2009-12-15 Flanders Interuniversity Institute For Biotechnology (Vib) Modification de glycosylation de proteine dans pichia pastoris
US7009045B2 (en) * 2000-07-14 2006-03-07 Archer-Daniels-Midland Company Transformation systems for flavinogenic yeast
EP1303293B1 (fr) 2000-07-27 2008-12-03 Genentech, Inc. Administration sequentielle de cpt-11 et d'apo 2l polypeptide
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1487480B1 (fr) 2001-05-01 2015-10-07 The Regents of The University of California Molecules hybrides pour le traitement des maladies immunitaires
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
JP4361791B2 (ja) 2001-08-29 2009-11-11 ジェネンテック・インコーポレーテッド マイトジェン活性を有するＢｖ８核酸及びポリペプチド
ATE486092T1 (de) 2001-09-18 2010-11-15 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
EP1553912A4 (fr) 2002-06-07 2007-08-08 Genentech Inc Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
PT1585966E (pt) 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CA2496060C (fr) 2002-09-11 2015-08-04 Genentech, Inc. Purification de proteines par chromatographie a echange d'ions
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
CA2499843A1 (fr) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
CA2503330A1 (fr) 2002-10-29 2004-05-13 Genentech, Inc. Compositions et methodes de traitement de maladies liees au systeme immunitaire
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CA2504144A1 (fr) 2002-11-26 2004-06-10 Genentech, Inc. Compositions et procedes pour le diagnostic de maladies de nature immune au moyen d'un polypeptide pro7
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
US7118901B2 (en) * 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
ATE387494T1 (de) * 2002-12-20 2008-03-15 Hoffmann La Roche Hitzelabile desoxyribonuklease i-varianten
CA2513113A1 (fr) 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
EP1460425A1 (fr) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Enzymes déglycosylés pour conjugués
EP1610820B2 (fr) 2003-04-04 2013-08-21 Genentech, Inc. Preparations d'anticorps et de proteines a forte concentration
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
MXPA06000347A (es) 2003-07-08 2006-03-28 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (fr) 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1673457B1 (fr) * 2003-08-25 2011-05-18 Funzyme Biotechnologies SA Nouvelles proteines fongiques et acides nucleiques codant pour celles-ci
AU2004291141B2 (en) 2003-11-17 2009-06-11 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
CA2486195C (fr) * 2003-12-05 2012-03-06 Stephan Glaser Carboxypeptidase b exprimee par ecombinaison et sa purification
PL2311873T3 (pl) 2004-01-07 2019-01-31 Novartis Vaccines And Diagnostics, Inc. Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
WO2005078074A2 (fr) 2004-02-13 2005-08-25 Novozymes A/S Variants de protease
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ES2339789T3 (es) 2004-07-20 2010-05-25 Genentech, Inc. Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
US20090136490A1 (en) 2004-11-10 2009-05-28 Diadexus, Inc. Ovr110 antibody compositions and methods for use
ATE462726T1 (de) 2005-01-07 2010-04-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
RU2290434C1 (ru) * 2005-06-02 2006-12-27 Общество с ограниченной ответственностью "БиоГениус" Штамм дрожжей pichia pastoris 2-2 - продуцент тромбоцитарного фактора роста человека (pdgf-bb) и способ получения тромбоцитарного фактора роста человека
EP1871163A2 (fr) 2005-06-06 2008-01-02 Genentech, Inc. Nouvelles interruptions geniques, compositions et methodes associees
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
ATE513921T1 (de) 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
PL1926749T3 (pl) * 2005-09-14 2011-12-30 Sanofi Aventis Deutschland Cięcie prekursorów insuliny przez wariant trypsyny
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
KR101442266B1 (ko) 2005-11-18 2014-11-04 그렌마크 파머수티칼스 에스. 아. 항-알파2 인테그린 항체 및 이의 용도
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2638821A1 (fr) 2006-02-17 2007-10-11 Genentech, Inc. Nouvelles disruption geniques, compositions et procedes associes
SG170728A1 (en) 2006-03-23 2011-05-30 Novartis Ag Anti-tumor cell antigen antibody therapeutics
EP2004689A4 (fr) 2006-04-05 2010-06-02 Abbott Biotech Ltd Purification d'anticorps
CA2647277A1 (fr) 2006-04-05 2007-11-08 Genentech, Inc. Methode d'utilisation du boc/cdo pour moduler l'emission des signaux du hedgehog
EP2010662A2 (fr) 2006-04-19 2009-01-07 Genentech, Inc. Nouvelles disruptions génétiques, compositions et procédés les concernant
AU2007244683A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2044111B1 (fr) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Ciblage du facteur h du système complémentaire destiné au traitement de maladies
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
SI2059535T1 (sl) 2006-08-18 2014-03-31 Novartis Ag Za prlr specifiäśno protitelo in njegove uporabe
EP2069502B1 (fr) 2006-09-27 2014-02-26 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
US7829674B2 (en) 2006-10-27 2010-11-09 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
AU2007313822A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
JP5519287B2 (ja) 2006-11-02 2014-06-11 ダニエル・ジェイ・カポン 可動部を備えたハイブリッド免疫グロブリン
CA2667376A1 (fr) 2006-11-14 2008-05-22 Genentech, Inc. Modulateurs de la regeneration neuronale
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
EP2104513B1 (fr) 2006-11-27 2015-05-20 diaDexus, Inc. Compositions d'anticorps ovr110 et leurs procédés d'utilisation
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
EA200900767A1 (ru) 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
WO2008097497A2 (fr) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Blocage de voie de vegf
DK2436781T3 (en) 2007-02-22 2016-01-11 Genentech Inc Methods for the detection of inflammatory bowel disease
KR101812400B1 (ko) 2007-04-03 2017-12-27 옥시레인 유케이 리미티드 분자의 글리코실화
JP5989299B2 (ja) 2007-05-30 2016-09-07 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． リゾホスファチジン酸結合のための組成物と方法
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
SG10201608952QA (en) 2007-06-07 2016-12-29 Genentech Inc C3b antibodies and methods for the prevention and treatment of complement- associated disorders
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
RU2511410C3 (ru) 2007-07-16 2021-06-15 Дженентек, Инк. АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US9845355B2 (en) 2007-07-16 2017-12-19 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP3441402A1 (fr) 2007-10-30 2019-02-13 Genentech, Inc. Purification d'anticorps par chromatographie à échange de cations
BRPI0820343A2 (pt) 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
ES2395784T3 (es) 2007-11-12 2013-02-15 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnosis de la influenza
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
CA2713504A1 (fr) 2008-01-31 2009-08-13 Genentech, Inc. Anticorps et immunoconjugues anti-cd79b et leurs procedes d'utilisation
CN102084002B (zh) * 2008-03-03 2014-09-10 Abbvie公司 用于转化酵母的方法
MX2010009885A (es) 2008-03-10 2010-11-30 Theraclone Sciences Inc Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
CA2719201A1 (fr) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Molecules neutralisantes d'antigenes viraux
SI2279412T1 (sl) 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
CN102112147B (zh) 2008-06-02 2014-05-21 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138、和cs1肽
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
WO2010034015A2 (fr) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulation de la voie de complément alternative
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN104689316A (zh) 2008-10-22 2015-06-10 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
NZ592436A (en) 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
WO2010078376A2 (fr) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Anticorps conjugués à un polymère spécifiques de fc et leur utilisation en diagnostic
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
TW201038286A (en) 2009-04-01 2010-11-01 Genentech Inc Anti-FcRH5 antibodies and immunoconjugates and methods of use
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
AU2010249787A1 (en) 2009-05-20 2011-12-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
DK2440228T3 (en) 2009-06-08 2018-12-17 Amunix Operating Inc Glucose regulating polypeptides and methods for their preparation and use
NZ621868A (en) 2009-06-08 2015-10-30 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
CA2766842A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Augmentation de la production cellulaire par mecanotransduction
SG178177A1 (en) 2009-07-31 2012-03-29 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (fr) 2009-09-25 2011-03-31 Xoma Technology Ltd. Procedes de criblage
DK2483399T3 (da) 2009-09-29 2019-05-13 Univ Gent Hydrolyse af mannose-1-phospho-6-mannose-binding til phospho-6-mannose
WO2011047267A1 (fr) 2009-10-15 2011-04-21 Genentech, Inc. Facteurs de croissance chimériques des fibroblastes avec spécificité de récepteur modifiée
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US20120328609A1 (en) 2009-10-22 2012-12-27 Genentech, Inc. Modulation of Axon Degeneration
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056497A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
WO2011056502A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
WO2011056494A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
KR20130055555A (ko) 2009-11-19 2013-05-28 옥시레인 유케이 리미티드 효모 스트레인 생성용 포유류 유사 복합 ｎ-글리칸들
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011080050A2 (fr) 2009-12-11 2011-07-07 Novartis Ag Molécules de liaison
SG181496A1 (en) 2009-12-18 2012-07-30 Csl Ltd Method of purifying polypeptides
RU2609658C2 (ru) 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
AU2010334383B2 (en) 2009-12-21 2014-10-02 Centre Hospitalier Universitaire Vaudois (Chuv) Synergic action of a prolyl protease and tripeptidyl proteases
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
WO2011104604A2 (fr) 2010-02-23 2011-09-01 Glenmark Pharmaceuticals S.A. Anticorps anti-intégrine alpha-2 et leurs utilisations
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
MX2012011112A (es) 2010-03-31 2012-10-15 Boehringer Ingelheim Int Anticuerpos anti-cd40.
EP4450523A3 (fr) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
RU2636461C2 (ru) 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
BR112012033121B1 (pt) 2010-06-25 2019-08-20 Institut Pasteur De Lille Métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
CN103108887A (zh) 2010-07-22 2013-05-15 葛兰素史密丝克莱恩生物有限公司 新的抗原结合蛋白
WO2012021786A2 (fr) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Compositions d'anticorps anti-hemagglutinine et ses méthodes d'utilisation
EP2420250A1 (fr) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anticorps anti-syndecan-4
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012027494A1 (fr) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Réactifs bispécifiques de ciblage
EP2611465A4 (fr) 2010-08-31 2014-06-04 Theraclone Sciences Inc Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
EP2616481A4 (fr) 2010-09-15 2014-04-02 Aligna Technologies Inc Production biologique de produits chimiques aromatiques à partir de composés dérivés de lignine
CA2810909A1 (fr) 2010-09-20 2012-03-29 Abbvie Inc. Purification d'anticorps par chromatographie a lit mobile simule
KR101979220B1 (ko) 2010-09-29 2019-05-16 옥시레인 유케이 리미티드 인산화된 n-글리칸들의 탈-만노실화
EP2622088A2 (fr) 2010-09-29 2013-08-07 Oxyrane UK Limited Mannosidases capables d'éliminer la coiffe des liaisons mannose-1-phospho- 6-mannose et de démannosyler les n-glycanes phosphorylés, et méthodes facilitant l'assimilation des glycoprotéines par des cellules de mammifères
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
EP2624852B1 (fr) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Utilisations diagnostiques et thérapeutiques de fragments de la moésine
KR101571940B1 (ko) 2010-10-08 2015-11-25 상하이 켁신 바이오테크 씨오., 엘티디. 면역성 혈소판 감소증과 관련된 모에신 단편
CA2814026C (fr) 2010-10-08 2017-07-11 Shanghai Kexin Biotech Co., Ltd. Fragments de la moesine associes a l'anemie aplasique
WO2012045274A1 (fr) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Modulateurs de la moésine et leurs utilisations
KR101641756B1 (ko) 2010-10-08 2016-07-21 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 단편 및 그의 용도
SI2635601T1 (sl) 2010-11-04 2017-01-31 Boehringer Ingelheim International Gmbh Anti-il-23-protitelesa
AU2011338892A1 (en) 2010-11-05 2013-05-23 Abbvie Inc. Efficient and effective supplement screening for the development of chemically defined media in cell culture
WO2012058726A1 (fr) 2010-11-05 2012-05-10 Transbio Ltd Marqueurs de cellules progénitrices endothéliales et leurs utilisations
WO2012064619A1 (fr) * 2010-11-10 2012-05-18 Merck Sharp & Dohme Corp. Locus de pichia pastoris codant pour des enzymes dans la voie biosynthétique de la proline
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
BR112013016235B1 (pt) 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
CN103687619A (zh) 2011-02-14 2014-03-26 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (fr) 2011-03-10 2012-09-13 Hco Antibody, Inc. Production recombinante de mélanges d'anticorps monocaténaires
WO2012125735A1 (fr) 2011-03-15 2012-09-20 Abott Laboratories Approche intégrée à isolement et purification d'anticorps
CN103533929A (zh) 2011-03-15 2014-01-22 特罗科隆科学有限公司 用于流行性感冒的治疗和诊断的组合物和方法
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
JP6248029B2 (ja) 2011-03-31 2017-12-13 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストの投与方法
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
KR20200067220A (ko) 2011-07-11 2020-06-11 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
MX2014001736A (es) 2011-08-17 2014-03-31 Genentech Inc Inhibicion de angiogenesis en tumores refractarios.
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
WO2013041687A1 (fr) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Molécules de liaison bispécifiques pour 5t4 et cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN118515766A (zh) 2011-11-16 2024-08-20 勃林格殷格翰国际有限公司 抗il-36r抗体
CA2857168C (fr) 2011-12-01 2020-10-27 Protevobio, Inc. Inhibiteurs proteiques du complement et des voies du vegf, et procedes d'utilisation associes
CN112877370A (zh) 2011-12-16 2021-06-01 布拉斯科南美公司 经修饰的微生物和使用其制造丁二烯的方法
WO2013091903A1 (fr) 2011-12-22 2013-06-27 Novo Nordisk A/S Anticorps anti-canal crac
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
BR112014015933A2 (pt) 2011-12-30 2019-09-24 Oxyrane Uk Ltd métodos e materiais para reduzir a degradação das proteínas recombinantes
KR20140117565A (ko) 2012-01-19 2014-10-07 유니버시티 오브 신시내티 비글리코실화 아포리포단백질 a-iv를 이용하여 당뇨병을 치료하는 방법
SG11201404486QA (en) 2012-01-31 2014-11-27 Genentech Inc Anti-ig-e m1' antibodies and methods using same
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
AU2013234042B2 (en) 2012-03-15 2017-11-02 Oxyrane Uk Limited Methods and materials for treatment of Pompe's disease
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158275A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de culture cellulaire pour réduire des espèces acides
US9550818B2 (en) 2012-04-27 2017-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for use of vascular endothelial growth factor antagonists
EP4039275A1 (fr) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anticorps anti-il-23p19
TW201348246A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
AU2012385960B2 (en) 2012-07-25 2017-04-13 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
EP3919069A1 (fr) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Peptides xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions
ES2689080T3 (es) 2013-01-02 2018-11-08 Glenmark Pharmaceuticals S.A. Anticuerpos que se unen a TL1A y sus usos
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014136065A2 (fr) 2013-03-05 2014-09-12 Oxyrane Uk Limited Production de sulfatase de type i catalytiquement active
PL2968466T3 (pl) 2013-03-13 2018-11-30 F.Hoffmann-La Roche Ag Preparaty o zmniejszonym utlenianiu
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
PT2968467T (pt) 2013-03-13 2020-07-28 Hoffmann La Roche Formulações de oxidação reduzida
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
RU2694055C2 (ru) 2013-03-13 2019-07-09 Дженентек, Инк. Составы антител
WO2014151901A1 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Amélioration de la performance de la culture de cellules de mammifère au moyen d'une supplémentation de milieux d'alimentation en tensioactifs
HK1206755A1 (en) 2013-03-14 2016-01-15 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
EP2970375A1 (fr) 2013-03-14 2016-01-20 AbbVie Inc. Composition d'espèces faiblement acides et leurs méthodes de production utilisant la chromatographie de déplacement
WO2014142882A1 (fr) 2013-03-14 2014-09-18 Abbvie Inc. Purification de protéine utilisant une chromatographie de déplacement
EP2970446A1 (fr) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Constructions d'anticorps pour m2 et cd3 de grippe
AR095348A1 (es) 2013-03-15 2015-10-07 Genentech Inc Medios de cultivo celular y métodos de producción de anticuerpos
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
AU2014233393B2 (en) 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
WO2014160753A1 (fr) 2013-03-27 2014-10-02 Genentech, Inc. Utilisation de biomarqueurs pour évaluer le traitement de troubles gastro-intestinaux inflammatoires par des antagonistes de l'intégrine bêta7
LT3004162T (lt) 2013-05-31 2020-06-10 Genentech, Inc. Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
CN105308067B (zh) 2013-06-07 2020-07-24 诺和诺德股份有限公司 制备成熟胰岛素多肽的方法
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
CA2925310C (fr) 2013-09-27 2022-12-06 Genentech, Inc. Formulations d'anticorps anti-pdl1
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3647324A1 (fr) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Procédés de traitement de cancers au moyen d'antagonistes de liaison d'axe pd-1 et de taxanes
WO2015095423A2 (fr) 2013-12-17 2015-06-25 Genentech, Inc. Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015102341A1 (fr) 2013-12-30 2015-07-09 재단법인 의약바이오컨버젼스연구단 Anticorps monoclonal anti-krs et son utilisation
CA2934965A1 (fr) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Nouveaux anticorps anti-baff
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
CN111808276A (zh) 2014-03-25 2020-10-23 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
BR112016020053A2 (pt) 2014-03-27 2018-02-20 Genentech, Inc. métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
EP3149187B1 (fr) 2014-05-30 2020-04-29 Braskem S.A. Micro-organismes modifiés comprenant un système optimisé pour l'utilisation d'oligosaccharides et procédés pour les utiliser
EP3145951A1 (fr) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
MX377344B (es) 2014-07-31 2025-03-07 Amgen Res Munich Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
EP3193932B1 (fr) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Formulations d'anticorps
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
HK1243931A1 (zh) 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016120764A1 (fr) 2015-01-26 2016-08-04 Centre Hospitalier Universitaire Vaudois (Chuv) Prolyl-endopeptidases d'aspergillus oryzae et utilisation associée dans la dégradation de polypeptides
HK1244512A1 (zh) 2015-02-04 2018-08-10 健泰科生物技术公司 突变型smoothened及其使用方法
WO2016126638A1 (fr) 2015-02-04 2016-08-11 Boehringer Ingelheim International Gmbh Méthodes de traitement de maladies inflammatoires
CN113209289A (zh) 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
WO2016141111A1 (fr) 2015-03-03 2016-09-09 Xoma (Us) Llc Traitement d'une hyperinsulinémie post-prandiale et d'une hypoglycémie après chirurgie bariatrique
WO2016144773A1 (fr) 2015-03-06 2016-09-15 Abbvie Inc. Glycoprotéines arabinosylées
EP3277716B1 (fr) 2015-04-03 2020-06-24 XOMA Technology Ltd. Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1
WO2016168282A1 (fr) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Méthodes de traitement de maladies
JP6907124B2 (ja) 2015-04-17 2021-07-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
PL3303619T3 (pl) 2015-05-29 2020-10-05 F. Hoffmann-La Roche Ag Metylacja promotora PD-L1 w chorobach nowotworowych
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
PL3334763T3 (pl) 2015-08-11 2024-12-02 WuXi Biologics Ireland Limited Nowe przeciwciała anty-pd-1
CN108026160A (zh) 2015-09-07 2018-05-11 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 新型igfr-样受体及其用途
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
JP6956417B2 (ja) 2015-12-24 2021-11-02 オキシレイン ユーケー リミテッド ヒトα−Ｎ−アセチルガラクトサミニダーゼポリペプチド
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
CA3007491A1 (fr) 2015-12-30 2017-07-06 Genentech, Inc. Utilisation de derives du tryptophane pour formulations proteiques
PT3411402T (pt) 2016-02-03 2022-02-01 Amgen Inc Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
PL3430054T3 (pl) 2016-03-15 2022-05-23 Chugai Seiyaku Kabushiki Kaisha Sposoby leczenia nowotworów z zastosowaniem antagonistów wiązania z osią PD-1 i przeciwciał anty-GPC3
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
RU2744959C2 (ru) 2016-03-23 2021-03-17 Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд Новые анти-pd-l1 антитела
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
JP6728392B2 (ja) 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
EP3464354B1 (fr) 2016-06-02 2021-07-28 Bloom Diagnostics AG Anticorps se liant à une hormone anti-müllérienne (amh) humaine et leurs utilisations
CN118530358A (zh) 2016-08-01 2024-08-23 佐马美国有限公司 甲状旁腺激素受体1（pth1r）抗体和其用途
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
EP3526252A2 (fr) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Méthodes de traitement de maladies avec anticorps il-23a
EP3526248A4 (fr) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions et méthodes de traitement d'une lésion du système nerveux central
US20190352374A1 (en) 2017-01-30 2019-11-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel igfr_like 2 receptor and uses thereof
EP4620975A3 (fr) 2017-02-02 2025-12-24 Amgen Research (Munich) GmbH Composition pharmaceutique à ph bas comprenant des constructions d'anticorps entrant en contact avec des lymphocytes t
WO2018152496A1 (fr) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika
EP3596126A4 (fr) 2017-03-15 2021-03-03 Tsinghua University Nouveaux anticorps anti-trkb
CN110461877A (zh) 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 抗il-36r抗体联合治疗
WO2018182284A1 (fr) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 Anticorps se liant spécifiquement à la région n-terminale de la lysyl-arnt synthétase exposée sur une membrane cellulaire
EP3615569A1 (fr) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus d'epstein barr
AR111773A1 (es) 2017-05-05 2019-08-21 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
EP3655430A1 (fr) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus de l'hépatite b
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
IL275054B2 (en) 2017-12-11 2025-11-01 Amgen Inc Continuous manufacturing process for bispecific antibody products
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3755718A1 (fr) 2018-02-21 2020-12-30 Celgene Corporation Anticorps de liaison à bcma et leurs utilisations
EP3768725A4 (fr) 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited Nouveaux anticorps anti-tim-3
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
WO2019195561A2 (fr) 2018-04-06 2019-10-10 BioLegend, Inc. Agents anti-tétraspanine 33 et compositions et procédés pour la fabrication et l'utilisation de ces agents
WO2019213416A1 (fr) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps et méthodes de diagnostic, de prévention et de traitement d'infection par le virus d'epstein barr
TWI890148B (zh) 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
EA202190094A1 (ru) 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против cd40 для применения в лечении аутоиммунного заболевания
WO2020033485A1 (fr) 2018-08-08 2020-02-13 Genentech, Inc. Utilisation de dérivés du tryptophane pour de l-méthionine pour une formulation protéique
CN112867735B (zh) 2018-09-07 2025-05-09 埃泰美德(香港)有限公司 双特异性抗原结合蛋白及其用途
KR102739487B1 (ko) 2018-09-21 2024-12-10 제넨테크, 인크. 3중-음성 유방암에 대한 진단 방법
WO2020068557A1 (fr) 2018-09-25 2020-04-02 BioLegend, Inc. Agents anti-tlr9 et compositions et procédés pour les préparer et les utiliser
US11505614B2 (en) 2018-09-28 2022-11-22 Amgen Inc. Antibodies binding to soluble BCMA
CN112789058A (zh) 2018-10-11 2021-05-11 安进公司 双特异性抗体构建体的下游加工
MX2021004684A (es) 2018-10-23 2021-06-04 Glycardial Diagnostics S L Anticuerpos especificos para apoj glucosilada y usos de los mismos.
WO2020132810A1 (fr) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation
WO2020136232A1 (fr) 2018-12-28 2020-07-02 Transgene Sa Protéine m2 à propriété immunosuppressive
EP3941938A1 (fr) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Récepteurs de lymphocytes t spécifiques de l'antigène de maturation des lymphocytes b pour le traitement du cancer
AU2020248645A1 (en) 2019-03-27 2021-10-28 Tigatx, Inc. Engineered IgA antibodies and methods of use
MY206253A (en) 2019-05-09 2024-12-05 Boehringer Ingelheim Int Anti-sema3a antibodies and their uses for treating eye or ocular diseases
CA3141504A1 (fr) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Nouvelle molecule de liaison cldn18.2
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CA3152665A1 (fr) 2019-08-27 2021-03-04 Tonix Pharma Limited Polypeptides tff2 modifies
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
US20230125690A1 (en) 2019-09-20 2023-04-27 Jae-sung Bae Antibody for detecting acetylation of cox2 protein, and uses thereof
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4093771A1 (fr) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
CN115551894A (zh) 2020-03-12 2022-12-30 以明生物免疫医疗公司 新型抗lilrb4抗体和衍生产物
EP4121459A1 (fr) 2020-03-19 2023-01-25 Amgen Inc. Anticorps contre la mucine 17 et leurs utilisations
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
HUE073185T2 (hu) 2020-04-15 2026-01-28 Genentech Inc Rézveszteség csökkentés
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
KR102871588B1 (ko) 2020-05-26 2025-10-17 베링거 인겔하임 인터내셔날 게엠베하 항-pd-1 항체
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
WO2021257497A1 (fr) 2020-06-15 2021-12-23 Sarepta Therapeutis, Inc. Anticorps anti-virus adéno-associés et fragments de ceux-ci
JP2023531406A (ja) 2020-06-16 2023-07-24 ジェネンテック， インコーポレイテッド トリプルネガティブ乳がんを処置するための方法および組成物
EP3939999A1 (fr) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
WO2022093640A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
WO2022093641A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
CA3199931A1 (fr) 2020-11-06 2022-05-12 Amgen Inc. Constructions polypeptidiques se liant a cd3
US20230406887A1 (en) 2020-11-06 2023-12-21 Amegen Inc. Antigen binding domain with reduced clipping rate
IL302586A (en) 2020-11-06 2023-07-01 Amgen Res Munich Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
WO2022133191A2 (fr) 2020-12-18 2022-06-23 Kiniksa Pharmaceuticals, Ltd. Compositions de protéines et leurs procédés de production et d'utilisation
CA3215594A1 (fr) 2021-04-02 2022-10-06 Agnieszka KIELCZEWSKA Constructions de liaison a mageb2
JP2024519523A (ja) 2021-04-26 2024-05-15 スアンズ バイオファーマシューティカル カンパニー，リミテッド 二重特異性抗体薬物コンジュゲート
JP2024529411A (ja) 2021-07-23 2024-08-06 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー Ｉｇｆｒ－ｌ１抗体およびその使用
US20250049939A1 (en) 2021-12-10 2025-02-13 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
TW202342515A (zh) 2021-12-22 2023-11-01 瑞士商Ｃｄｒ生命股份有限公司 抗c3抗體及其抗原結合片段及其用於治療眼疾病之用途
KR20230098953A (ko) 2021-12-27 2023-07-04 경북대학교 산학협력단 Asm에 특이적으로 결합하는 항체 및 이의 용도
US20250242002A1 (en) 2022-01-29 2025-07-31 Peking University First Hospital Truncated forms of iga protease, fusion proteins comprising a truncated form of iga protease and uses thereof
EP4238988A1 (fr) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Anticorps dirigés contre le sars-cov-2 et leurs utilisations
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
WO2024032891A1 (fr) 2022-08-11 2024-02-15 Vib Vzw Levure glyco-modifiée pour la production de protéines thérapeutiques
KR20250071294A (ko) 2022-08-22 2025-05-21 압데라 테라퓨틱스 인크. Dll3 결합 분자 및 이의 용도
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
PE20251849A1 (es) 2022-10-18 2025-07-22 Tubulis Gmbh Novedosos anticuerpo anti-tpbg y conjugados-anticuerpo-droga basados en el mismo, metodos terapeuticos y usos de los mismos
CN120166939A (zh) 2022-10-18 2025-06-17 Tubulis 股份有限公司 新型抗napi2b抗体和基于该抗体的抗体-药物-偶联物、治疗方法及其用途
EP4640715A1 (fr) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Complexe polypeptidique multi-spécifique ciblant gprc5d
EP4640708A1 (fr) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Nouvel anticorps anti-gprc5d
WO2024243217A1 (fr) 2023-05-25 2024-11-28 BioLegend, Inc. Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
UY40797A (es) 2023-06-14 2024-12-31 Amgen Inc Moléculas captadoras de enmascaramiento de células t
WO2025036848A1 (fr) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps anti-muc16 et utilisations
WO2025043134A1 (fr) 2023-08-24 2025-02-27 Rezolute, Inc. Formulations à haute concentration pour anticorps anti-récepteur de l'insuline et leurs utilisations
WO2025072313A1 (fr) 2023-09-27 2025-04-03 BioLegend, Inc. Anticorps anti-gpc4
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
WO2025144974A1 (fr) 2023-12-29 2025-07-03 Absci Corporation Variants de domaine fc pour extension de demi-vie et leurs utilisations
TW202545992A (zh) 2024-01-23 2025-12-01 中國大陸商上海藥明生物技術有限公司 靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
WO2025171378A1 (fr) 2024-02-09 2025-08-14 Rezolute, Inc. Modulation du récepteur de l'insuline pour hyperinsulinisme associé à une tumeur
WO2025212738A1 (fr) 2024-04-04 2025-10-09 BioLegend, Inc. Anticorps se liant à chi3l1 et leurs fragments de liaison à l'antigène
WO2025230843A2 (fr) 2024-05-01 2025-11-06 BioLegend, Inc. Anticorps se liant au kir et leurs fragments se liant à l'antigène
EP4653010A1 (fr) 2024-05-14 2025-11-26 35Pharma Inc. Variants du récepteur de l'activine de type iib et leurs utilisations
WO2026006472A2 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions d'anticorps il-1r1 et leurs procédés de production et d'utilisation
WO2026039642A1 (fr) 2024-08-16 2026-02-19 Ardeagen Corporation Conjugués d'anticorps anti-mésothéline et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068969B (en) * 1980-02-05 1983-07-27 Upjohn Co Gene expression
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4617274A (en) * 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
ATE42338T1 (de) * 1982-05-19 1989-05-15 Unilever Nv Hefe des genus kluyveromyces, modifiziert zur expression von preprothaumatin oder seinen verschiedenen allelischen und modifizierten formen oder maturationsformen.
NO840200L (no) * 1983-01-28 1984-07-30 Cefus Corp Glukoamylase cdna.
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast

Also Published As

Publication number Publication date
CA1297438C (fr) 1992-03-17
PT81402A (en) 1985-11-01
JPS61108383A (ja) 1986-05-27
ZA858180B (en) 1986-06-25
MX430A (es) 1993-11-01
FI94428C (fi) 1995-09-11
FI94428B (fi) 1995-05-31
PT81402B (pt) 1987-11-11
ES8609464A1 (es) 1986-09-01
AU4875685A (en) 1986-06-12
JPH0681593B2 (ja) 1994-10-19
ATE68204T1 (de) 1991-10-15
AU572353B2 (en) 1988-05-05
DE3584353D1 (de) 1991-11-14
EP0183070B1 (fr) 1991-10-09
NO178975B (no) 1996-04-01
US4879231A (en) 1989-11-07
EP0183070A2 (fr) 1986-06-04
IL76763A (en) 1991-03-10
IE852473L (en) 1986-04-30
DK496485A (da) 1986-05-01
DK496485D0 (da) 1985-10-29
FI854145L (fi) 1986-05-01
ES548306A0 (es) 1986-09-01
FI854145A0 (fi) 1985-10-23
IE58217B1 (en) 1993-08-11
IL76763A0 (en) 1986-02-28
GR852609B (fr) 1986-03-04
SG43092G (en) 1992-06-12
EP0183070A3 (en) 1987-09-30
NO854334L (no) 1986-05-02

Similar Documents

Publication Publication Date Title
NO178975C (no) Fremgangsmåte til transformering av en gjærart av slekten Pichia
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
AU563860B2 (en) Autonomous dna replication sequence from pichia yeast
KR850005454A (ko) 환상 폴리펩타이드의 제조방법
ATE56755T1 (de) Stamm von clostridium acetobutylleum und verfahren zur herstellung desselben.
EP0248637A3 (fr) Induction de l'expression de gènes régulée par le galactose dans la levure
PT81052B (pt) Processo de preparacao de saccharomyces recombinantes
EP0172914A4 (fr) Souche de pseudomonas solanacearum m4s, composition la contenant et permettant de combattre les maladies vehiculees par le sol des solanacees, et son procede d'utilisation.
EP0343388A3 (fr) Espression de l'interferon-gamma dans des levures méthylotrophiques
ES2000401A6 (es) Un procedimiento para la produccion de acido 7b -(d-5-amino-5-carboxivaleramido)-3-hidroximetil-7-metoxi-3-cefem-4-carboxilico
DE3566670D1 (en) Process and intermediates for sorbinil
CA2002480A1 (fr) Procede de production de lysozyme humain
IE43702L (en) Obtaining e. coli enterotoxin
ES8605574A1 (es) Procedimiento para preparar una alcoholdeshidrogenasa

Legal Events

Date Code Title Description
MK1K Patent expired